Carregant...
Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers co-driven by mutant EGFR containing T790M and MET
Tyrosine kinase inhibitors (TKIs) that target the epidermal growth factor receptor (EGFR) are effective in most NSCLC patients whose tumors harbor activating EGFR kinase domain mutations. Unfortunately, acquired resistance eventually emerges in these chronically treated cancers. Two of the most comm...
Guardat en:
| Autors principals: | , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2012
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3389159/ https://ncbi.nlm.nih.gov/pubmed/22552292 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-11-3720 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|